Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A)  by Kramerova, Irina et al.
Biochimica et Biophysica Acta 1772 (2007) 128–144
www.elsevier.com/locate/bbadisReview
Molecular and cellular basis of calpainopathy
(limb girdle muscular dystrophy type 2A)
Irina Kramerova a, Jacques S. Beckmann b, Melissa J. Spencer a,⁎
a Departments of Neurology and Pediatrics and UCLA Duchenne Muscular Dystrophy Research Center, University of California, Los Angeles,
Neuroscience Research Building, 635 Young Dr. South, Los Angeles, CA 90095-7334, USA
b Department of Medical Genetics, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland
Received 26 May 2006; received in revised form 7 July 2006; accepted 13 July 2006
Available online 15 July 2006Abstract
Limb girdle muscular dystrophy type 2A results from mutations in the gene encoding the calpain 3 protease. Mutations in this disease are
inherited in an autosomal recessive fashion and result in progressive proximal skeletal muscle wasting but no cardiac abnormalities. Calpain 3 has
been shown to proteolytically cleave a wide variety of cytoskeletal and myofibrillar proteins and to act upstream of the ubiquitin-proteasome
pathway. In this review, we summarize the known biochemical and physiological features of calpain 3 and hypothesize why mutations result in
disease.
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(LGMD) are due to mutations in genes encoding structural
proteins that make up the cytoskeletal scaffold of muscle. These
LGMDs are slowly progressive and involve wasting in the
proximal shoulder and pelvic girdle muscles. The observation
that mutations in proteins with similar cellular functions
produce overlapping clinical phenotypes suggested a common
pathophysiological pathway for all the limb girdle muscular
dystrophies [1]. Thus, when researchers discovered that
mutations in a protease called calpain 3 (CAPN3 or p94)
caused LGMD type 2A, it suggested that in spite of the similar
clinical phenotype, pathogenesis in these disease entities might
differ [2]. The mutation in CAPN3 was the first identified
muscular dystrophy mutation found to occur in an enzyme
rather than in a structural protein. Since then, hundreds of
pathogenic mutations in the CAPN3 gene have been described.
Of interest is the fact that numerous mutations lead to loss of
calpain 3 protein, indicating that lack of this protease leads to
pathogenic consequences. Early speculations about the function
of CAPN3 suggested that it might modulate members of the⁎ Corresponding author. Tel.: +1 310 794 5225; fax: +1 310 206 1998.
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doi:10.1016/j.bbadis.2006.07.002dystrophin–glycoprotein complex (DGC), since all previously
identified dystrophies had been shown to have some relation-
ship to these proteins. The possible link to the DGC remains,
however, cryptic. While indirect relationships between CAPN3
and the DGC have been described, such as CAPN3 cleavage of
the sarcoglycan binding protein filamin C [3], the preponder-
ance of the data that have been generated since that time suggest
that CAPN3 is more likely to be involved in disassembly of the
sarcomere and muscle cytoskeleton to allow for proper protein
turnover during muscle remodeling [4,5]. In this review, we will
describe the known, biochemical characteristics of calpain 3 and
features of calpainopathy. With this information in mind, we
will attempt to provide a cohesive explanation for the biological
function of calpain 3 and hypothesize why mutations in CAPN3
might be pathogenic.
1. Genetics and etiology of LGMD2A
The genetic study of the autosomal recessive form of limb
girdle muscular dystrophy (AR-LGMD) was prompted by the
uncovering of a cluster of LGMD patients in the southern part of
the isle of La Réunion. They all presented symptoms fitting the
classical description of LGMD (a term introduced in 1954 by
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neurologist Wilhelm Heinrich Erb [6,7]. Furthermore, these
patients belonged to a set of inter-related families, thus
facilitating the genetic quest for the etiologic gene. This study
led to the initial mapping of the disease locus to chromosome
15q [8], thereby providing an unambiguous demonstration for
the existence of this challenged and controversial clinical entity
[9,10]. The mapping assignment was soon confirmed on other
ethnic isolates. The inclusion of these large consanguineous
pedigrees allowed researchers to refine the incriminated
interval. These efforts eventually led, after a long and
painstaking 5 years search involving linkage mapping, physical
mapping [11,12], and association studies [13,14], to the
identification of etiologic mutations. All identified mutations
fell inside a previously known, yet totally unsuspected gene,
CAPN3, encoding the calpain 3 protease [15]. Initial descrip-
tions of this gene reported that in humans its 24 exons span
close to 53 kb of genomic DNA, leading to a transcript of
3.5 kb. Additional alternatively spliced exons and promoter
sequences were subsequently described, contributing to the
complexity of this gene's products and confounding analysis of
its function [16,17].
As these studies progressed, it soon became clear that the
LGMDs formed a genetically heterogeneous entity, involving at
least ten recessive forms and three dominant ones, referred to
collectively as LGMD2 and LGMD1, respectively [18,19]. A
minority of LGMD patients is still unaccounted for by any of
these genes, thus suggesting the involvement of additional loci.
CAPN3 mutations account for the largest fraction of the AR-Table 1
Distribution of CAPN3 mutations by exon and mutation type
Exon number Exon length bp Variants
Non-pathogenic a Pathogenic
1 309 11 29
2 70 1 6
3 119 6 17
4 134 4 25
5 169 4 29
6 144 4 8
7 84 4 11
8 86 1 14
9 78 0 3
10 161 4 21
11 170 3 21
12 12 3 0
13 209 5 22
14 37 3 0
15 18 2 6
16 114 3 8
17 78 0 7
18 58 2 8
19 65 1 9
20 59 1 5
21 78 1 17
22 117 5 11
23 59 2 1
24 27 3 3
Total 2465 72 284
a Non-pathogenic or unclassified variant.LGMDs, varying regionally from 10 to 50% and reaching as
high as 80% in some ethnic populations [20]. Genetic
heterogeneity was also documented in isolated ethnic popula-
tions such as the inter-related northern and southern Indiana Old
Order Amish populations in which families with either
calpainopathies or beta-sarcoglycanopathies can be found
[21,22].
2. Mutations in the CAPN3 gene
Ten years later, there are now over 280 documented distinct
pathogenic CAPN3 mutations and a smaller number of
apparently neutral polymorphic or unclassified variants [23]
(Table 1). These mutations were documented in patients
covering wide geographic areas. All types of mutations have
been found, from gene inactivating mutations such as point
mutations leading to premature stop codons, splice sites or
frameshift mutations or even larger insertion/deletion type of
mutations to missense mutations that affect the primary
sequence of the protein, resulting often [20,24] (but not always)
[24,25] in loss of calpain 3′s proteolytic activity. With the
exception of founder effects in isolated populations, there are no
major predominant mutations and in most instances, mutation
screening still leads to the discovery of new mutations [26–28].
As many as three out of four newly examined CAPN3 alleles
present with new mutations. Nevertheless, some mutations are
encountered more frequently than others. For example,
c.550delA and c.2362_2363delinsTCATCT are present in
more than 144 and 143 (respectively) of the 1204 individuals,Types of pathogenic mutations
Missense Stop Frameshift Splice In frame deletion
19 0 8 0 2
3 1 2 0 0
12 1 1 2 1
16 1 2 4 2
22 2 3 1 1
2 1 3 2 0
6 2 1 2 0
8 2 1 3 0
3 0 0 0 0
15 1 4 1 0
15 0 4 2 0
0 0 0 0 0
15 1 3 3 0
0 0 0 0 0
0 0 3 2 1
3 0 5 0 0
2 0 3 1 1
1 0 2 4 1
7 0 1 0 1
3 1 2 0 0
7 3 3 4 0
5 0 4 1 1
1 0 0 0 0
0 0 0 3 0
165 16 55 36 12
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dystrophy database (http://www.dmd.nl), possibly reflecting
common ancestral founder mutations. This is particularly
striking in inbred populations, (e.g. the predominant
c.2362_2363delinsTCATCT encountered in patients from
Basque origin), as often indicated by the fact that they also
share a common haplotype around this mutation. Interestingly,
there remains a small but sizeable fraction of patients, for which
only one mutant allele of the CAPN3 gene is identified [29].
This raises the possibility that additional mutations may reside
in parts of the gene that were not scanned (for example in
remote regulatory regions) or that these patients are hemizygous
due to a large cryptic deletion in this region.
In addition to genetic heterogeneity in LGMD2A, unsus-
pected allelic heterogeneity was also encountered in small
inbred isolates, which were a priori considered to represent
homogeneous genetic isolates, each presumably reflecting a
unique founder mutation [13,21,30]. Based on genealogical
studies, the Réunion island LGMD2A pedigrees were thought
to form a megafamily related through multiple consanguineous
links that trace back to a single common ancestor who was one
of the first settlers of this island in the 17th century. Hence, the
present day families were expected to represent a clinically and
genetically homogeneous set. Their study eventually led to theFig. 1. CAPN3 mutations are predominantly missense mutations that occur in dom
mutations by type is represented. Missense mutations make up the largest type of C
CAPN3 coding region and protein domains. Nucleotides were clustered into 100 bp in
mutations was evident. This figure demonstrates that clusters can be observed in dounsuspected discovery of at least six distinct segregating
CAPN3 mutations [30,31]. Similar observations were reported
for the Basque LGMD2A community [32]. This extensive and
unexpected allelic heterogeneity created a puzzle, referred to as
the Réunion paradox. Different explanations were provided to
account for this apparent paradox invoking digenic [33] or
monogenic [34,35] inheritance.
The CAPN3 mutations span almost the entire length of the
CAPN3 gene, though this distribution is inhomogeneous (Fig.
1 or Table 1) sparing only one small exon (exon 12) on the
one hand, while showing a grouping of mutations in a subset
of exons, on the other hand. When the number of missense
mutations is plotted per scanning window of 100 bp, instead
of per exon (given that the latter vary widely in size), a
clustering of mutations can be observed (Fig. 1 and [36]).
Such standardization reveals a non-uniform distribution of
mutations, with clusters of missense mutations apparent
around domains IIa, IIb and III while a cluster of preserved
regions or cold spots is apparent in the IS1 and IS2 domains.
Many of these missense mutations have been modeled onto
the crystal structure of CAPN3 and from this analysis it could
be deduced that these mutations affect enzyme activity,
primarily through thorough disruption of domain movement
necessary for formation of the catalytic triad at the active siteains II and III. (A) A pie chart is shown in which the distribution of CAPN3
APN3 mutation. (B) Distribution of missense mutations along the length of the
tervals (1–100, 101–200, etc.) for the purpose of determining if any clustering of
mains IIa, IIb and III.
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these latter missense mutations that have been directly
investigated, it has been determined that several affect the
ability of CAPN3 to bind to titin (the relationship between
CAPN3 and titin will be discussed elsewhere in this article)
[24,25]. It is likely that additional mutations that impair
CAPN3/substrate interactions will be identified, although
these mutations are yet to be recognized. Hence, loss of
proteolytic activity and loss of titin anchorage are the two
ways in which CAPN3 mutations might be pathogenic.
Besides genetic variability, there is also frequent irregular-
ity in the severity of the clinical phenotype of LGMD2A,
leading to the suggestion that the genetic makeup of the
patients or second mutations might play an important role in
determining the symptoms, rate of progression and magnitude
of the disease (e.g. modifier alleles) [37,38]. For example, it
was observed that in two siblings with calpain deficiency one
manifested the disease as a metabolic myopathy while the
other as an advanced LGMD [38]. The report of LGMD
patients homozygous for null-type mutations demonstrated the
pathogenic nature of loss of this activity. However, attempts to
derive genotype–phenotype correlations are difficult, due to
the extensive heterogeneity of CAPN3 mutations; therefore,
these studies are mostly restricted to the study of patients
carrying two gene inactivation alleles or to patients belonging
to large consanguineous families (which could be homozygous
for a missense mutation). In general, it has been deduced that
carriers of two inactivating CAPN3 alleles tend to be more
severely affected with the disease and to display symptoms ofFig. 2. CAPN3 mutations cause severe muscular dystrophy. Panels A and B show pict
the patient in panel A. The patient in panel B shows atrophy of the biceps muscle.LGMD2A at an earlier age than carriers of missense
mutations.
3. Clinical phenotype of LGMD2A
The onset of LGMD2A is usually in the second decade of
life, although it has been documented to occur as early as age
2.5 and as late as age 49 [20,29,39–41]. Serum CK levels vary
from slightly elevated to as high as 50 times normal. A
proportion of the LGMD2A patients have severe contractures
[42]. The course of the disease is slow but progressive, leading
to loss of ambulation by approximately 1 or 2 decades after
diagnosis. Scapular winging and hip abductor sparing are two
common features with the primary muscles involved being the
glutei and hip adductors (Fig. 2). The clinical phenotype has
been shown to be highly variable, even in affected siblings,
especially with regard to calf hypertrophy [37]. In an MRI study
of 7 patients with LGMD2A by Muntoni and colleagues, the
predominantly affected muscles in ambulatory patients were in
the posterior compartment of the thigh and included the
adductors and semimembranous muscles [42]. Patients who
had reduced ambulation also showed involvement of the
posterior/lateral muscles of the thigh with relative sparing of
the sartorius and gracilis. In the calf, all patients showed signs of
disease in the soleus and medial head of the gastrocnemius with
sparing of the lateral head. In the upper body, the biceps was
strongly affected with relative sparing of the triceps. There are
no reports of cardiac or facial involvement in this disorder, a
feature that stands in great contrast with other forms of LGMD,ures of two patients with LGMD2A. Severe atrophy is apparent in all muscles of
Both patients stand on their toes due to contracture of the Achilles tendon.
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pathology likely stems from the fact that CAPN3 is not
detectable in cardiac tissue although the mRNA is expressed in
the heart during development [17,43]. Thus, there is selective
skeletal muscle involvement in LGMD2A, a feature that may
aid in the determination of whether a given patient should be
tested for CAPN3 mutations.
4. Histopathology
Biopsies from patients with LGMD show a typically
dystrophic appearance that consists of necrosis, regeneration,
fiber diameter variability, myofibrillar disorganization, and
fibrosis [40,41,44]. Abundant and disorganized mitochondria
have been observed in two studies in which electron microscopy
was performed [40,41]. These mitochondria are likely the basis
for the lobulated fibers that have been repeatedly reported in
human and mouse studies [25,41,45]. Large cohorts of patient
biopsies have been examined from countries such as Japan [41],
Italy [20], the Czech Republic [44] and Brazil [46] and these
studies all reported the same dystrophic picture mentioned
above; however, there are differences between these groups of
biopsies that are probably attributable to the ethnic make-up of
the subjects in a given group. For example, in a study of 21
biopsies from Japanese LGMD2A patients, the authors
observed fragmentation of nuclei and a predominance of type
I atrophic fibers [41]. These fragmented nuclei may have
derived from apoptotic cells in the later stages of the disease or
they could be due to generalized necrosis. In contrast,
Hermanova et al. described 14 cases of Czech LGMD2A
biopsies in which some patients showed a type I fiber
predominance while others had atrophic type II fibers along
with hypertrophic type I fibers [44]. In this latter study, the
atrophic type II fibers suggested a neurogenic lesion because of
the severe atrophy observed. In an Italian cohort, the observance
of subsarcolemmal glycogen accumulation was reported [20].
Thus, there are features that are common to all LGMD2A
biopsies (necrosis, regeneration, mitochondrial disorganization)
but also additional features (fiber type specific atrophy,
glycogen accumulation) that may or may not present, depending
on the genetic make-up of the patients being examined.
Zatz and colleagues examined biopsies from patients from a
large consanguineous family (that were homozygous for the
null type R110X mutation) in which biopsies were available
from 4 affected patients and 3 family members who carried the
same mutation but were essentially asymptomatic (with the
exception of elevated CK) [46]. While the affected patients had
a typically dystrophic phenotype, the three other pre-clinical
biopsies looked essentially normal with the exception of one
focal area of necrosis in one fascicle. A fourth asymptomatic
individual was identified carrying a P82L mutation and she also
showed the same picture of normal looking fibers and isolated
necrosis. The authors concluded that the early disease features
observed in these pre-clinical biopsies suggest that LGMD2A
pathogenesis is distinctive from other dystrophies. This
conclusion is presumably based on the infrequent detection of
necrotic areas in the LGMD2A biopsies, a finding that is incontrast to what is frequently observed in muscles from other
asymptomatic LGMD patients.
5. CAPN3 and the ubiquitous calpains
CAPN3 (also known as p94) is a member of the calpain
family of intracellular soluble cysteine proteases, a large clan of
calcium dependent enzymes (for review see [47]) (Fig. 3).
Genome sequencing projects have revealed the presence of
calpain genes in various organisms from yeast and fungi to C.
elegans, Drosophila and mammals. At least 13 mouse and 14
human family members have been identified, some of which are
ubiquitous and others which are tissue specific. Two of these
family members, called calpains 1 and 2, expressed by most
mammalian tissues, are the best characterized. The ubiquitous
calpains exist as heterodimers consisting of a large 80 kDa,
catalytic subunit and a small 28 kDa, regulatory subunit that are
non-covalently associated through their C terminal EF hand
domains [47,48]. All of the protease activity is contained in the
large subunit while the small subunit appears to be vital for
correct folding, regulation and stability of the large subunit.
Examination of the structure of the ubiquitous calpains has
allowed for the designation of four defined domains in the large
catalytic subunit and two domains in the regulatory subunit
(Figs. 3 and 4). The domains of the large subunit include a pro-
peptide domain (domain I), a catalytic domain containing the
three active site residues (domain II), a third domain containing
a calcium and phospholipid binding C2 domain (domain III)
and a fourth calmodulin-like Ca2+ binding domain containing 5
EF hand sequences (domain IV). The small subunit consists of
domain V, which is glycine and proline rich, and domain VI,
which is similar to domain IV with 5 EF hand regions.
Additional calcium binding sites exist in domain II that play a
role in calcium dependent activation [49].
CAPN3 differs from the ubiquitous calpains in several ways.
First, while calpains 1 and 2 are ubiquitously expressed
isoforms, CAPN3 transcripts are primarily found in skeletal
muscle. The predominant 3.5 kb long mRNA for CAPN3 is
expressed at least ten fold higher in muscle than the mRNAs for
the conventional calpains [15]. Second, CAPN3 does not
interact with a small subunit; instead, it appears to homodimerize
through its PEF domains (Fig. 4) [50,51]. Third, while most of
the CAPN3 molecule has approximately 50% homology with
the large subunit of conventional calpains, CAPN3 has three
additional insertion sequences that are found (1) at the N
terminus (47 amino acids called NS); (2) within domain II (48
amino acids called IS1); and (3) between domains III and IV (77
amino acids called IS2) [52]. A nuclear localization signal is
present near IS2, but the nuclear localization of CAPN3 has not
been concretely confirmed.
There are no sequences that are paralogous to the IS1 and
IS2 genomic sequences in the Genbank database. It is
hypothesized that they either confer a tissue specific function
or that they regulate CAPN3 since these sequences distin-
guish CAPN3 from the other known calpain isoforms. Yeast
two-hybrid mapping [53] has suggested that the IS2 domain
may mediate the interaction between CAPN3 and titin (please
Fig. 3. Calpain family of proteases. Mammalian calpain family members are shown, grouped into “typical” and “atypical” calpains. The ubiquitous (conventional)
calpains exist as two subunit heterodimers of a small and large subunit. CAPN3 is shown below the conventional calpains. The NS, IS1 and IS2 regions are shown in
yellow. EF hand regions are shown as yellow ovals. Domain numbers are indicated by roman numerals. Atypical calpains are shown as a group in the bottom part of the
figure. These calpains lack one or more of the four domains. Note the conservation of the protease domain (domains IIa and IIb) between all calpain family members.
Domains IIa and IIb are also referred to as domain I and II by some investigators (see Figs. 4 and 5).
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modeling used in conjunction with biochemical studies, has
predicted that the IS1 region blocks the active site of the
molecule until it is autolytically cleaved to allow substrate
access [54]. Modeling studies have also placed these se-
quences towards the outside of the molecule, suggesting that
they might participate in protein–protein interactions [36].
Alternatively spliced isoforms of CAPN3 (that lack NS, IS1
or IS2 or both) are expressed in several other tissues including
rodent lens (Lp82) [55], retina (Rt88) [56] and cornea (Cn94)
[57]. Interestingly, the CAPN3 transcript alternatively splices
out IS1 and IS2 containing exons during skeletal muscle
development [17]. Following birth, these CAPN3 specific
sequences are retained and are only re-expressed during muscle
regeneration [17], suggesting that they serve a developmental
role. Support for this hypothesis comes from transgenic studies
in which transgenic over expression of the IS1 deleted form of
CAPN3 in adult skeletal muscle leads to developmentally
immature muscles [58].
The alternatively spliced isoforms lacking IS1 or IS2 are
proteolytically active and appear to be more stable than full-
length CAPN3 [3,58]. This increased stability may relate to an
increased requirement for calcium to achieve activation [59].
The loss of the IS1 sequence removes two of the three autolytic
sites in the molecule [50,54], the absence of which also
contributes to the stabilization [3,5,17,58,59]. So far, no
differences in substrate specificities have been identified
between the isoforms however, the inhibitor E64 differentially
inhibits full length CAPN3 compared to the alternatively
spliced isoforms in lens or peripheral blood cells, suggesting
that substrate binding may differ between these species thatexpress or lack the IS1 and IS2 domains [60]. Collectively, these
studies suggest that the IS1 and IS2 insertions may be important
for determining substrate specificity, regulation of activity and
calcium dependence of CAPN3 and its activation. The
differential splicing of CAPN3 in development, post-natal and
regenerating muscles suggests that this gene's products may
serve different roles in developing vs. adult muscle.
A few other cell types have been shown to expressCAPN3 but
the significance of the protein in these tissues is yet to be
investigated. CAPN3 has been detected in peripheral blood
mononuclear cells [61], astrocytes in the brain [62] and in
myeloid precursor cells [63]. Interestingly, a recent paper
described a cohort of patients that were previously diagnosed
with idiopathic eosinophilia and it was observed that 6 of these
individuals hadmutations inCAPN3. At this time, it is not clear if
the myositis is derived from primary pathogenesis of the muscle
or the myeloid cells; however, this observation extends the
spectrum of diseases that involve CAPN3mutations. In addition,
the identification of amonogenic disorder that shows tremendous
variability in phenotypic consequences is a theme that is being
observed repeatedly in the area of neuromuscular disorders.
6. Activation of CAPN3
The structure of calcium-free calpain 2 (a conventional
calpain) was obtained in 1999. In these studies, the authors
showed that the large subunit consists of four subdomains
occupying one general oval plane connected to an N-terminal
anchor peptide [64]. The small subunit also resides in the same
oval plane. While the model of four subdomains fit with the
previously predicted structure that had been based on the
Fig. 4. Crystal structure of CAPN3 shown as a homodimer. Shown in panel A is a diagram of the four domains of the large subunit of m-calpain (top) and CAPN3
(bottom). The three additional sequences of NS, IS1 and IS2 are shown in yellow. Shown in panel B is a graphical representation of the crystal structure of two CAPN3
molecules homodimerizing through their C termini. NS, IS1 and IS2 regions are indicated by arrows. To the right of the crystal structure is a bar figure that represents a
side view, demonstrating how the two CAPN3 molecules interact through the five EF hand domains. Figure taken from Ravulapalli et al. [51]. Please note that domains
I and II in this figure correspond to domains IIa and IIb in Fig. 3.
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that the protease domain, can be subdivided into subdomains I
and II. Domains I and II contain the three catalytically active
residues that form a triad in the cleft between them. In general,calpains 1 and 2 are inactive in the absence of calcium due to the
large distance (10.5 Å) between these residues (cysteine 105,
histidine 262 and asparagine 286 in calpain 2) that make up the
catalytic triad [49,67]. Activation of calpains occurs in two
Fig. 5. Model of the activation mechanism of CAPN3. Shown is a graphic
representation of proposed activation mechanism of CAPN3 from Garcia Diaz
et al. [70]. In this model, Davies and colleagues propose that activation
happens in two steps involving intra and intermolecular cleavages. In step 1,
calcium binds, allowing domain movement and formation of the catalytic triad
(cysteine, histidine and asparagine). This active site formation is followed by
intramolecular cleavages at the N terminal region of both NS and IS1. In step
2, intermolecular cleavage occurs at the C terminal regions of NS and IS1. The
latter step allows for the enzyme to be fully active.
135I. Kramerova et al. / Biochimica et Biophysica Acta 1772 (2007) 128–144steps. First, binding of calcium to domains III, IV and VI helps
to break the electrostatic salt links between domains I and IIa
and between the acidic residues in domain III with the lysine
residues in subdomain IIb [68]. Calcium binding also occurs in
the active site to allow for it to properly form the catalytic triad
between Cys, His and Asn [49]. To form a catalytically active
site, the 10.5 Å distance between the catalytic residues must be
decreased to 3.7 Å [49,64,69]. Thus Ca2+ binding to numerous
sites along the molecule in conjunction with cleavage of the N
terminal peptide allows for the release of constraints and proper
alignment of the active site residues.
Information regarding the activation mechanism of CAPN3
has been derived from modeling studies that have predicted the
structure of normal and mutated CAPN3 as well as traditional
biochemical studies [36,54,59,70]. Early analysis of CAPN3
showed that it rapidly autolyzed if it was expressed in vitro, or
following homogenization of muscle tissue [50,71]. These
studies also showed that deletion of the IS1 or IS2 domains
increased CAPN3's half-life and it has been speculated that this
increase in stability relates to a reduction in calcium sensitivity
[71]. Follow up studies in which CAPN3 was expressed in
insect cells allowed for some traditional biochemical character-
ization of the enzyme to be carried out. In these early studies it
was determined that full length CAPN3 was calcium dependent,
but required much less calcium than the conventional isoforms
[72]. While the authors could express a small amount of soluble
and active CAPN3, the levels of expression were not
sufficiently high to allow for biochemical analysis.
The catalytic core domains of all calpains are similar and the
critical residues for Ca2+ binding are well conserved, suggesting
that Ca2+-dependent activation may be a common feature for all
calpains including CAPN3. Recently, Davies and colleagues
utilized a truncated form of CAPN3 that only consists of
domains I and II (referred to as p94I–II) [54,70,73]. This
truncated form of the enzyme is stable in EDTA but autolytically
cleaves in the presence of calcium, thus enabling the use of
p94I–II to facilitate understanding of the biochemical properties
of CAPN3 activation. Together, with molecular modeling based
on the known crystal structure of calpain I (domains I/II), these
studies have demonstrated that intramolecular and intermole-
cular autolytic cleavage occurs in two sites of NS and at least two
sites in IS1. IS1 acts like an internal propeptide, removal of
which must occur in order to make the active site available to
hydrolyze exogenous substrates. NS does not have a similar
function because activation of a NS deletion mutant is
indistinguishable from that of the full-length p94I–II [54]. It
has also been shown in these studies that the two autolytically
produced fragments, both of which contain critical catalytic
residues, remain associated non-covalently in the presence of
Ca2+. Based on their observations, the authors proposed a two-
stage model of activation of the proteolytic core of CAPN3
shown in Fig. 5. According to this model, upon Ca2+ binding, the
CAPN3 proteolytic core undergoes a conformational change
similar to the ubiquitous μ- and m-calpains [49,70]. This change
allows for release of structural constraints such as salt bridges,
and formation of the catalytic triad that makes up the active site.
The low calcium requirement of CAPN3 might be due to thepresence of the IS1 and IS2 insertions that may add flexibility to
the molecular structure, thus facilitating formation of the active
site [59]. Incidentally, several studies have shown that deletion
mutants of the CAPN3 proteolytic core (p94I–II) lacking IS1
[54] or full length CAPN3 lacking IS1 [3,17] are also fully active
in the presence of Ca2+.
Due to the unstable nature of CAPN3, only a limited amount
of information about the calcium requirement of full-length
CAPN3 is available. While calpain 2 is known to require
millimolar concentrations and calpain 1 is known to require
micromolar concentrations, CAPN3 appeared to require
nanomolar concentrations in early studies [72]. However,
there is no agreement about the specific Ca2+ requirement for
CAPN3 activity in the literature. For example, it was shown by
one group that CAPN3 underwent rapid autolysis even in the
presence of EDTA [50] but another group reported that CAPN3
136 I. Kramerova et al. / Biochimica et Biophysica Acta 1772 (2007) 128–144was stable in the presence of EGTA [72]. Studies of the catalytic
core fragment of CAPN3 showed that the full-length p94I–II
and its deletion mutant lacking NS and IS1 require Ca2+ for
activity. Unlike studies using the recombinantly expressed
protein, p94I–II had half maximal activity values of 150 μM
CaCl2 for p94I–II and 90 μMCaCl2 for the IS1-deletion mutant
[70]. However, it was observed in these studies that slow
accumulation of autoproteolytic fragments was detected even at
substoichiometric levels of Ca2+ and in the presence of EDTA.
7. CAPN3 in physiological processes
The exact mechanisms involved in the pathogenesis of
LGMD2A are still unknown. Since CAPN3 is a protease with a
potentially broad range of substrates, there is a high probability
that it is involved in regulating multiple physiological
processes. This diverse role for CAPN3 means that its absence
or mutations in CAPN3 can affect many pathways in muscle
cells. Indeed, studies using cell culture, human biopsies and
mouse models have revealed a potential involvement of CAPN3
in the regulation of processes as diverse as apoptosis, muscle
cell differentiation, sarcomere formation, muscle remodeling
and regulation of the cytoskeleton. Below we discuss current
knowledge of the role of CAPN3 in these processes and its
possible contribution to the pathogenesis of LGMD2A.
8. CAPN3 and NFκB-mediated apoptosis
The hypothesis that loss of CAPN3 proteolytic activity leads
to myonuclear apoptosis was based on the histological
identification of TUNEL-positive myonuclei in biopsies from
patients with LGMD2A [74]. In this study, the observation was
made that biopsies from LGMD2A showed an approximately
100 fold higher frequency of myonuclear apoptosis than that
found in biopsies from other muscular dystrophy patients,
suggesting that apoptosis may be a specific pathogenic feature
of LGMD2A; yet overall, the fraction of apoptotic myonuclei
was still very small [74]. Interestingly, in this study, apoptotic
myonuclei were detected in morphologically normal fibers that
were found in patches of variable size. In the same study, IkBα,
a negative regulator of NFκB, was found to accumulate in
apoptotic myonuclei, while NFκB was found to accumulate
under the sarcolemmal membrane. These findings led to the
hypothesis that IkBα is a substrate for CAPN3 and that in the
absence of proteolytically active CAPN3, IkBα concentration
increases. This accumulation of IkB would lead to stabilization
of the IkBα/NFκB complex in the cytoplasm and inhibition of
NFκB signaling, leading to the loss of NFκB-mediated
expression of survival genes. To confirm this hypothesis,
IkBα was shown to be a substrate for CAPN3 when the two
proteins were co-expressed in insect cells [74]. However, if this
hypothesis were correct, one would expect to observe
accumulation of IkBα in protein extracts from LGMD2A
biopsies, which was not shown. Instead, an accumulation of
NFκB was seen in 2 LGMD2A patients (out of 8 total). While
these studies are intriguing, the NFκB inhibition hypothesis
contradicts recent data obtained using in vivo mouse models ofNFκB activation and repression [75]. In those studies, NFκB
inhibition due to transgenic expression of an IkB mutant
resistant to degradation had no effect on muscle mass or
pathology, whereas NFκB activation, achieved through
enhanced degradation of IkB, caused severe muscle wasting.
Thus, while apoptosis may be a mechanism occurring in
LGMD2A, it is neither clear that loss of NFκB signaling is the
basis for its occurrence nor whether this apoptosis is a primary
or an ancillary feature of the pathophysiological process of
LGMD2A.
Two mouse models of LGMD2A have been generated, and
both of them have been used to test the question of apoptosis in
this disease [25,76]. One mouse model of LGMD2A carried an
in-frame deletion of 63 amino acids at the catalytic domain of
CAPN3, that most likely eliminated proteolytic activity but
preserved other properties of CAPN3 such as binding to titin
[76]. In this study, the authors reported the observation that
apoptotic nuclei were a pathological feature of calpainopathy;
however, because double staining for a sarcolemmal marker
was not performed in this investigation, it was unclear if the
apoptotic nuclei were located inside or outside of the myofibers.
The frequency of occurrence of observed apoptotic nuclei was
also not reported. Studies on the second model of CAPN3-null
mice also revealed the presence of apoptotic nuclei, but
demonstrated that they were not apoptotic myonuclei but rather,
apoptotic nuclei from infiltrating immune cells [25]. In this
case, double staining for apoptotic nuclei in conjunction with
staining for a sarcolemmal marker clearly showed that apoptotic
nuclei were located outside of the myofibers and were co-
stained with an immune cell marker [25]. This contradiction
may indicate that apoptosis is not a primary mechanism of
LGMD2A but that it is a secondary event in the pathogenic
process. Since the CAPN3-deficient mouse models have a
rather mild phenotype compared to LGMD2A patients, it is
possible that apoptotic myonuclei, being one of the late
manifestations of the disease, may not be readily detectable in
mice.
9. Role of CAPN3 in regulation of the cytoskeleton
Several cytoskeletal proteins have been shown to be
substrates for CAPN3 in various in vitro assays [3,5]. Among
those, probably, the most interesting is filamin C, a muscle-
specific isoform of filamin that interacts with actin, myotilin,
γ- and δ- sarcoglycans, and was hypothesized to provide a
signaling link between the sarcolemma and Z disk of
myofibrils [77–79]. Recently, a novel type of autosomal
dominant myofibrillar myopathy was described that is
associated with a mutation in the filamin C gene [80]. In
this study, a pathogenic mutation occurred in the C-terminal
region of filamin C that prevented dimerization of the protein
[80]. Interestingly, this form of myofibrillar myopathy showed
clinical signs of LGMD and cytoplasmic aggregates that
contained not only filamin C but other sarcolemmal and Z
disk proteins [80]. CAPN3 was shown to interact with and
cleave filamin C at the C-terminal region in both in vitro
transcription–translation assays and in co-expression
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interaction of filamin C with the sarcoglycans, since cleavage
of filamin C inhibited its ability to interact with γ- and δ-
sarcoglycans [3]. The ability of CAPN3 to cleave filamin was
confirmed in independent co-expression experiments [5];
however, no evidence was provided in any of these studies
that filamin 3 serves as a physiological substrate for CAPN3
in vivo using CAPN3 knockout mice.
A number of other cytoskeletal proteins have been identified
as potential substrates for CAPN3 such as talin, vinexin and
ezrin [5]. Taveau et al., 2003 investigated the relationship
between the CAPN3 isoforms and the cytoskeleton in a cell
culture system [5]. In these studies it was shown that
overexpression of full length CAPN3 in cultured cells caused
cell rounding associated with disorganization of the actin
cytoskeleton and focal adhesions. CAPN3 mutant forms with
either deletion or mutation of the internal cleavage sites (IS1
region) were not able to recapitulate this phenotype, lending
support for the idea that cleavage of IS1 is important for
proteolytic activity [5]. At the same time, an alternatively
spliced isoform of CAPN3 carrying an IS1 deletion was able to
cleave a number of cytoskeletal proteins with approximately the
same efficiency as full-length CAPN3 [5]. Even though these
studies demonstrated that CAPN3 cleaves many cytoskeletal
proteins in vitro, future studies are necessary to confirm that any
are bona fide in vivo substrates before drawing any conclusion
about the role of CAPN3 in regulation of the cytoskeleton.
10. CAPN3 and dysferlin
Dysferlin is a member of the ferlin family of transmem-
brane proteins shown to be involved in vesicle trafficking and
membrane repair (for review see Bansal and Campbell, 2004
[81]). Mutations in dysferlin cause three clinically distinct
autosomal recessive muscle diseases, LGMD2B, Miyoshi
myopathy and distal anterior compartment myopathy [82–
84]. Dysferlin knock-out mice have been generated and it
was demonstrated using these mice that in the absence of
dysferlin, vesicles that provide an additional membrane to
reseal the disrupted sarcolemma accumulate at the site of
repair but don't fuse, suggesting a role for dysferlin in
muscle membrane fusion [85]. Intriguingly, a secondary
reduction of CAPN3 was reported in at least some patients
with LGMD2B and Miyoshi myopathy [86]. Reciprocally
decreased sarcolemmal staining of dysferlin was occasionally
found in patients with calpainopathy [87]. Recently it was
shown that dysferlin and CAPN3 biochemically interact in
co-immunoprecipitation assays [88]. Thus, the reciprocal loss
of CAPN3 and dysferlin in LGMD2A and LGMD2B
biopsies and the finding of a biochemical interaction between
these proteins leads to the suggestion that dysferlin functions
to stabilize CAPN3 at the membrane and visa versa.
Alternatively, CAPN3 may play a role in dysferlin-mediated
plasma membrane repair. Others have hypothesized that
CAPN3 might function in membrane repair by regulating
annexins A1 and A2, proteins that interact with dysferlin
[89]. If CAPN3 were important in dysferlin's ability tofunction in membrane repair, one would expect to find
disrupted plasma membrane repair in CAPN3-deficient
mouse models. The issue of membrane instability in
calpainopathy has been investigated using both available
mouse models. Richard et al. reported a significant loss of
membrane integrity in CAPN3-deficient mice, even without
exercise [76]. However, follow up studies by the same group
with the same mice did not reveal any membrane alterations,
even after downhill and treadmill training [90]. We also did
not find any indication of significant membrane damage in
CAPN3 knock-out mice after they were challenged with
downhill running exercise for 4 days [4]. Thus, the question
of the possible involvement of CAPN3 in processes mediated
by dysferlin remains to be answered. There is a possibility
that while membrane integrity is not affected by loss of
calpain, membrane repair may be jeopardized. Studies
specifically addressing this issue need to be undertaken.
11. CAPN3 and sarcomeric proteins
The localization of CAPN3 in skeletal muscle has been
unclear. While CAPN3 has been localized at the N2-line [91], Z
disc, M-line, costameres, myotendinous junctions and nuclei
[5,74,91] in various reports, none of these studies have been
confirmed using CAPN3-null muscles as a negative control.
Yeast two hybrid assays have identified two regions of titin that
bind to CAPN3 called the N2 line and the M line [53,92].
Recently, those CAPN3–titin interactions were confirmed at the
protein level [25]. Therefore, an important site for CAPN3
anchorage in the cell is on the muscle-specific protein titin at the
N2 and M line regions. Future studies will be necessary to
confirm if alternative cellular sites of localization exist.
Titin (also called connectin) is a giant cytoskeletal protein that
spans half of the sarcomere and is important for both sarcomere
assembly and function [93]. Duringmyofibrillogenesis, titin acts
as a molecular ruler that controls alignment of actin and myosin
filaments and acts as a scaffold for other sarcomeric proteins. In
mature muscle, titin forms a third myofilament system that
provides the muscle with elasticity and passive tension [94]. The
elastic properties of titin are achieved primarily through folding
and unfolding of a unique proline-rich PEVK region located just
after the N2 line region in the sarcomere [93,95,96]. Another
unique sequence in the titin molecule is the kinase domain
located at the C-terminal end (near the M-line of the sarcomere).
Recent studies have demonstrated that titin serves as a molecular
sensor of mechanical stretch that activates this kinase domain
and subsequently regulates gene expression [97].
It has been proposed that titin might serve a stabilizing role
for CAPN3 keeping it in an inactive state and preventing its
rapid autolysis [98,99]. It is also possible that titin directly
controls CAPN3 activity or access to its substrates. Support for
the hypothesis that titin serves to stabilize CAPN3 from
autoproteolytic degradation comes from several observations.
First, CAPN3 is very stable in whole muscles until the muscle is
subjected to homogenization, a process that might dislodge
CAPN3 from its anchored position. Second, overexpression of
wild type CAPN3 has a deleterious effect on cultured cells [5]
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produce any phenotype in adult differentiated muscles in vivo
[58]. Finally, CAPN3 is not stable when expressed in vitro [71].
Taken together, these observations suggest that the absence of
titin or disruption of the titin/CAPN3 interaction is deleterious
for CAPN3 function.
Although a role for titin as a “molecular depot” for CAPN3
still needs to be proven in direct experiments, several recent
observations lend support for this hypothesis. A titin mutation
that leads to a severe muscular dystrophy was identified in the
mdm mouse that carries a LINE insertion at the N2 line region
of titin [98]. This insertion, causes mis-splicing of the titin
mRNA, leading to a deletion near the N2 line and loss of the
CAPN3/titin interaction in yeast two-hybrid assays [100].
Muscle extracts from mdm mice show a decreased concentra-
tion of CAPN3, lending support for the hypothesis that titin
regulates CAPN3 stability [98]. Furthermore, patients with
tibial muscular dystrophy, caused by a mutation in the M-line
fragment of titin, also have a secondary CAPN3 deficiency [99].
Finally, some of the pathogenic CAPN3 mutations that are not
predicted to affect proteolytic activity of CAPN3 showed a
reduced binding affinity to titin in yeast two hybrid assays [24]
and in direct protein–protein interaction assays [25]. Interest-
ingly, a recently identified pathogenic LGMD2A mutation
(Ser606Leu) was identified in the IS2 domain [101]. This
mutation is unlikely to affect activation of the molecule and
therefore, the mutation likely affects anchorage to titin. These
studies suggest that the CAPN3/titin interaction is not only
important but that loss of this interaction can have pathogenic
consequences.
To address the question about the physiological role of the
CAPN3–titin interaction in vivo, mouse models have been
generated that either lack or overexpress CAPN3 in the mdm
background [102]. As shown previously, overexpression of
CAPN3 in the muscles of a wild type mouse is not toxic and
does not produce any phenotype [58]. In contrast, over-
expression of CAPN3 in mdm mice results in a worsening of
the mdm phenotype [102]. These data strongly support the
hypothesis that titin serves as an important buffer and regulator
of CAPN3 activity. In wild type muscle, CAPN3 appears to be
sufficiently sequestered on titin; however, in the mdm mouse,
one of the two CAPN3 binding sites is absent. This loss of
anchorage is clearly deleterious for muscle. Double mutants that
lack CAPN3 on the mdm background, on the other hand, did
not show any change in the severity or progression of the mdm
phenotype suggesting that aberrant CAPN3 activity is not a
primary mechanism of mdm pathology [102].
It is now known that defects in several proteins that have
some association with titin, can cause muscular dystrophy
(Fig. 6) [3,25,80,98,99,103–108]. This “titin macromolecular
complex” (TMC) can therefore be considered to be a second
protein complex in which any one mutation in a complex
member is pathogenic. This idea has precedent in the dystrophin
glycoprotein complex (DGC) [108,109,1996,110–116], a large
protein complex that serves both structural and regulatory
functions in muscle [117]. It has been shown that defects in any
one of several members of the DGC or associated proteins cancause any of several muscular dystrophies that vary in severity
and age of onset [118]. Investigations of the structure of the DGC
in normal and DGC-mutant muscle has also provided convin-
cing evidence that mutations in a single DGC member can have
major effects on the ability of non-mutant DGC members to
assemble and function [119]. Thus, all proteins in this complex
subserve a common physiological function. If this functional
and structural interdependence were also present in the TMC, it
would help explain the common dystrophic consequences of
defects in any of several titin complex members. Thus,
understanding the relationship between titin and C3 and these
other TMC members may be critical in uncovering the
pathophysiological basis of several diseases and provide insight
into basic questions about the myogenic process.
The possibility that titin binding to CAPN3 serves to
modulate CAPN3 activity or put it in correct proximity to its
substrates may have important implications for the structure and
function of the TMC. CAPN3 may play an essential role in
regulating the structure and assembly of the TMC by proteolytic
modification of proteins that interact directly or indirectly with
titin [93]. This potential role for CAPN3 in regulating the
structure and function of the TMC is consistent with previous
findings concerning the function of other calpain isoforms that
can regulate cytoskeletal rearrangement and protein–protein
interaction by limited proteolytic cleavage [120]. Baculoviral
co-expression studies, in which different titin domains were co-
expressed with CAPN3 showed specific cleavage of M line and
PEVK regions of titin but not of N2 line of titin [25]. These
studies demonstrated that titin can serve as a substrate for
CAPN3 in regions adjacent to where it binds and lend support
for the idea that succinct cleavage of titin by CAPN3 may allow
for the exchange of proteins on the titin scaffold that is a
necessary occurrence for remodeling during myofibrillogenesis
and adaptation.
12. CAPN3 and sarcomere remodeling
Previous studies by our laboratories have shown that
overexpression of the alternatively spliced isoform of CAPN3
(minus exon 6) results in muscle that is developmentally
immature [58]. This led to the hypothesis that full length
CAPN3 may play a role in muscle maturation. To assess muscle
maturation in the absence of CAPN3, primary cultures were
generated from muscles of CAPN3 knock out mice (C3KO).
These cells have a defect in their ability to form sarcomeres
[25]. To determine if the abnormal myofibrillogenesis observed
in vitro might result in abnormal sarcomeres in vivo, electron
microscopy of adult C3KO muscles was carried out [25]. These
studies showed that the ultrastructure of C3KO sarcomeres in
vivo was also abnormal. In these studies, otherwise healthy
muscle fibers showed a misalignment of the edges of the A
bands, which is the myosin-containing region of the sarcomere
[25]. Thus, sarcomere formation and structure are abnormal in
the absence of CAPN3. While it is evident that humans and
mice lacking CAPN3 develop apparently normal and functional
muscles, this occurrence may be due to compensating factors
that are present in vivo but absent in vitro. The observation of
Fig. 6. Cartoon of a sarcomere and associated proteins that have mutations associated with muscular dystrophy. The localization of these proteins is shown. All proteins
with a blue asterisk have mutations that result in muscular dystrophy.
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abnormal sarcomere ultrastructure in otherwise healthy muscle
cells has led to the hypothesis that CAPN3 has a role in
sarcomere remodeling processes in adult muscles.
13. CAPN3 and post-natal muscle remodeling
In light of the abnormal sarcomeres observed in the C3KO
mice and the previously known role for calpains in muscle
protein turnover, the hindlimb suspension/reloading model was
used to investigate the question of CAPN3's role in muscle
remodeling [4]. In this procedure, mice are suspended by their
tails for 10 days, a process that unloads the hindlimb muscles.
During this period due to the lack of weight bearing, significant
muscle mass loss occurs [121]. After the muscles are allowed to
resume weight bearing (called “re-loading”), muscle mass is
slowly regained over a period of 7–10 days. The advantage of
using such a model is that muscle remodeling must occur if
both the atrophic and growth phases are to occur normally.
These studies demonstrated a reduction in the ability of C3KO
muscles to adapt to changes in load bearing because null
muscles did not change mass and cross sectional area as readily
as controls. In particular, muscle growth was severely reduced
in the knock out during reloading compared to controls. These
findings suggest that CAPN3 plays an important role in
removal and addition of myofibrillar proteins during muscle
adaptation.It is known that most muscle protein turnover is carried out
by the proteasome; however, it is also known that the
proteasome cannot degrade intact myofibrils [122,123]. Thus,
it is likely that an upstream proteolytic pathway must be
operating to release myofibrillar proteins from the sarcomere
to target them for ubiquitination and proteasomal degradation.
To determine if CAPN3 is acting upstream of the proteasome
during muscle remodeling, mice that were undergoing
remodeling were examined for overall ubiquitination levels
[4]. It was shown that overall ubiquitination is reduced in
reloaded muscles from C3KO compared to reloaded (weight
bearing) controls supporting the hypothesis that CAPN3 acts
upstream of the ubiquitin/proteasome pathway. This observa-
tion also suggests that CAPN3 must have multiple substrates
because global reductions in ubiquitination could be detected
by these methods.
14. Hypothetical mechanism by which loss of proteolytic
capability might lead to cell dysfunction
The intracellular milieu provides conditions under which
cellular proteins are continually damaged and then degraded by
the proteasome. Processes such as oxidation can damage
proteins, which can then become misfolded leading to protein
aggregation and cellular toxicity (Fig. 7). Numerous examples
exist in which loss of proteolytic capability via the ubiquitin/
proteasome pathway leads to disease. Alzheimer's disease,
Fig. 7. Flow chart demonstrating the pathogenic consequences of CAPN3 deficiency. Mutations in CAPN3 can lead to loss of proteolytic activity or loss of titin
anchorage. The latter is likely to reduce regulation of proteolytic activity or to remove CAPN3 from its substrates. Loss of proteolysis of substrates can cause
accumulation of proteins that can subsequently become damaged and then aggregate. These aggregates can impair proper muscle function and impair growth, leading
to muscular dystrophy.
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and several forms of cancer can result from mutations in
proteins associated with the protein degradation machinery
[124]. It is possible that accumulation of old and damaged or
misfolded proteins in muscle tissue can also lead to toxicity and
disease. These proteins form insoluble aggregates that recruit
some components of the ubiquitination and proteasomal
machinery as well as heat shock proteins of Hsp70 and small
Hsp families (reviewed in [125]). Even though no morpholo-
gically visible protein aggregates have been observed in C3KO
muscles, biochemical analysis showed accumulation of Hsp70
and Hsp25 in the insoluble fractions of C3KO muscles [4].
These results give support for the hypothesis that a reduced
capacity for normal protein turnover in muscles deficient for
CAPN3 can induce abnormal protein accumulation that leads to
a cell stress response and toxicity. Fig. 7 shows a flow diagram
in which this is described.
Involvement of CAPN3 in generalized proteolysis does not
exclude the possibility that CAPN3 plays a role in controlling
specific cellular pathways such as cytoskeletal rearrangements,
sarcomere formation and remodeling or apoptosis as was
suggested by numerous published studies [4,5,25,74,76].Taking into account that CAPN3 may have many substrates,
it is quite possible that LGMD2A develops from impairment of
several cellular processes rather than a single one. In vitro
studies have suggested that CAPN3 and ubiquitous calpains
may have overlapping sets of substrates. The significance of this
observation is that proteolytic activities of other calpains may be
able to partly compensate for the absence of CAPN3. At the
genetic level, it means that ubiquitous calpains may act as
genetic modifiers. Taking into account these characteristics of
CAPN3 (i.e. the pleiotropic nature of calpain mutations and the
presence of functionally redundant calpains) one can explain the
high variability in the phenotypic characteristics of the disease,
even within a family. Future analysis of mouse models of
LGMD2A and especially identification of in vivo substrates and
interactive partners of CAPN3 are crucial for our understanding
of LGMD2A pathogenesis and development of therapeutic
approaches.
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